Stephen C. Glover
CIK 1304406 · Chief Executive Officer · last filed 2026-06-03
Stephen C. Glover is a Chief Executive Officer who has filed 20 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for ONCY, was dated Jun 3, 2026. Across all open-market trades the lifetime net is +$137.9K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $5.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$5.02M
6
20
$137.9K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ONCY | Director | — | $0.79 | — | $0 | 1 | 2026-06-03 |
| PDSB | Director | 78,851 | $0.69 | $54.5K | $75.0K | 10 | 2026-03-03 |
| ZyVersa Therapeutics, Inc. (ZVSA) Delisted | Chief Executive Officer | — | $0.20 | — | $0 | 2 | 2025-07-15 |
| Ambrx Biopharma, Inc. (AMAM) Delisted | Director | 85,000 | $28.00 | $2.38M | $0 | 3 | 2024-03-07 |
| ZyVersa Therapeutics, Inc. (ZVSAW) Delisted | Chief Executive Officer | 492,756 | — | — | $0 | 1 | 2022-12-14 |
| INSM | President Follow-on Biologics | 47,716 | $104.13 | $4.97M | $62.9K | 3 | 2009-04-02 |
Recent Filings
20 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-03 | ONCY | Grant (A) | — | $0 | EDGAR |
| 2026-03-03 | PDSB | Grant (A) | — | $0 | EDGAR |
| 2025-07-15 | ZyVersa Therapeutics, Inc. (ZVSA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-11 | PDSB | Grant (A) | — | $0 | EDGAR |
| 2025-03-03 | PDSB | Buy (P) | +15,061 | $25.0K | EDGAR |
| 2024-07-18 | ZyVersa Therapeutics, Inc. (ZVSA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-25 | PDSB | Grant (A) | — | $0 | EDGAR |
| 2024-03-07 | Ambrx Biopharma, Inc. (AMAM) Delisted | Disp (D) | — | $0 | EDGAR |
| 2023-07-17 | PDSB | Grant (A) | — | $0 | EDGAR |
| 2023-06-09 | Ambrx Biopharma, Inc. (AMAM) Delisted | Grant (A) | +85,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.